Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trials

Axel Hauschild, Paolo A. Ascierto, Dirk Schadendorf, Jean Jacques Grob, Antoni Ribas, Felix Kiecker, Caroline Dutriaux, Lev Demidov, Célèste Lebbé, Piotr Rutkowski, Christian U. Blank, Ralf Gutzmer, Michael Millward, Richard Kefford, T Haas, Anthony M. D’Amelio, Eduard Gasal, Bijoyesh Mookerjee, Paul B. Chapman